| Names | |
|---|---|
| Preferred IUPAC name | 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one |
| Other names | Metamizole impurity N 1-Phenyl-3-methyl-2-pyrazolin-5-one Edolan Phenazone methyl |
| Pronunciation | /waɪn ˈfiː.nɪl θriː ˈmɛθ.ɪl faɪ pɪˈræz.əˌloʊn/ |
| Identifiers | |
| CAS Number | 89-25-8 |
| Beilstein Reference | Beilstein 107831 |
| ChEBI | CHEBI:77003 |
| ChEMBL | CHEMBL42799 |
| ChemSpider | 16616 |
| DrugBank | DB01143 |
| ECHA InfoCard | 05c814db-2ca7-410c-8242-6fef243a0f80 |
| Gmelin Reference | 87842 |
| KEGG | C10463 |
| MeSH | D011703 |
| PubChem CID | 7057 |
| RTECS number | UY8225000 |
| UNII | W463W6OQ88 |
| UN number | 2811 |
| Properties | |
| Chemical formula | C10H10N2O |
| Molar mass | 174.20 g/mol |
| Appearance | White to light yellow crystalline powder |
| Odor | Odorless |
| Density | 1.18 g/cm3 |
| Solubility in water | slightly soluble |
| log P | 1.64 |
| Vapor pressure | 4.1E-5 mmHg at 25°C |
| Acidity (pKa) | 7.46 |
| Basicity (pKb) | 4.20 |
| Magnetic susceptibility (χ) | -66.6·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.568 |
| Viscosity | 160.00 mPa.s (40°C) |
| Dipole moment | 3.52 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 256.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -70.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -2908 kJ mol-1 |
| Pharmacology | |
| ATC code | N02BB72 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H319 |
| Precautionary statements | P261, P280, P305+P351+P338, P337+P313 |
| Flash point | 124°C |
| Autoignition temperature | 580°C |
| Explosive limits | Lower explosive limit not found; upper explosive limit not found |
| Lethal dose or concentration | LD50 (oral, rat): 640 mg/kg |
| LD50 (median dose) | LD50 (median dose): 4920 mg/kg (oral, rat) |
| NIOSH | SN8750000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 5 mg/m³ |
| Related compounds | |
| Related compounds | Edaravone 4-Aminoantipyrine Dipyrone Antipyrine Metamizole |
| Section | Details |
|---|---|
| Product Name & IUPAC Name | Routine factory documentation covers both common and IUPAC names. Application forms, COAs, and batch sheets record "1-Phenyl-3-methyl-5-pyrazolone" as the product name. Formal IUPAC registration recognizes the structure as 1-Phenyl-3-methyl-2,4-dihydro-5H-pyrazol-5-one. Most plant records reflect the common trade name for batch and process records; regulatory filings often require the IUPAC form. |
| Chemical Formula | Raw material receipts, QC specimen files, and finished goods logs all track the molecular formula C10H10N2O. Monitoring trace elements or byproduct patterns depends on this backbone for NMR, GC-MS, or other release analytics. |
| Synonyms & Trade Names | Common synonyms registered in batch management systems include Phenazone-5-one, Mepirizole, PMZ, and 1-Phenyl-3-methylpyrazol-5-one. Customer requisitions and technical contracts sometimes specify unique local or proprietary synonyms, particularly in colorant or pharmaceutical intermediate sectors. Synonym usage varies according to downstream application, especially where regulatory traceability or multi-lingual safety paperwork is required. |
| HS Code & Customs Classification | For export, customs documentation typically classifies 1-Phenyl-3-methyl-5-pyrazolone under HS Code 2933.99, which covers heterocyclic compounds with nitrogen hetero-atom(s) only, not elsewhere specified. Country-specific customs declarations may impose alternate digits at the subclass level, depending on targeted end-use or presence in controlled substance annexes. Freight and shipment paperwork, including CMR and IMDG forms, require strict HS code cross-referencing with batch purity and intended use, given regulatory sensitivity for pharmaceutical or pigment intermediates. |
The product typically crystallizes as a solid under controlled plant conditions. Form, color, and odor vary slightly with product grade and synthesis method. Commercial lots present as yellow to off-white crystalline solids. Minor color deviation can indicate batch-to-batch process control drift or raw material impurity carryover. Odor is faint or absent in high-purity grades; notable odor points to residual solvents or unreacted intermediates.
Melting point and boiling point are relevant benchmarks for quality control, with typical values matching literature data in controlled production. These parameters shift outside expected ranges if impurity load increases. Density varies by packing density and residual solvent level in lower-purity or technical grades.
Quality depends on the exclusion of oxidative and acidic impurities. Light and moisture sensitivity may emerge at higher storage temperatures or with insufficiently sealed packaging. Grades with tighter impurity limits show greater process stability downstream, particularly for sensitive formulations or further chemical transformation.
Solubility depends on grade, crystal form, and residual moisture. Pharmaceutical and reagent grades display higher clarity and fewer residues when dissolved in specified solvents. Technical and industrial grades may generate particulates that require filtration before use. Preparation procedures often consider temperature, agitation, and solvent purity to ensure clarity and reproducibility for downstream synthesis or formulation.
| Property | Pharma Grade | Tech Grade | Custom Spec |
|---|---|---|---|
| Appearance | Yellow-white crystal | Yellow powder | Defined by client |
| Assay | Defined by pharma standard | Application-specific | Defined by contract |
| Moisture | Low (< defined max) | Higher permissible | To requirement |
| Impurity Profile | Controlled by relevant pharmacopoeia | Process-dependent | Confirmed in batch |
Critically monitored impurities include starting material residues, by-product isomers, and decomposition fragments. High-purity batches demonstrate minimal signature impurities, typically confirmed by validated chromatographic analysis. Actual allowed impurity levels are dictated by end-use—API applications require tighter limits compared to dyes or industrial usage.
Assay and impurity testing employ high performance liquid chromatography, gas chromatography, and melting point determination. Standardization follows internationally recognized methods where available; custom test protocols may apply for specialized uses. Test frequency, instrument calibration, and analyst certification form integral parts of the quality system.
Batch consistency depends on the purity and lot-traceability of phenylhydrazine, ethyl acetoacetate, and other critical reagents. Key suppliers are regularly audited to prevent variability in baseline impurity levels.
The classical route involves a condensation of phenylhydrazine with ethyl acetoacetate, followed by cyclization under controlled conditions. Exact parameters—temperature, catalyst, pH, concentration—depend on required purity and production scale. Process selection balances throughput, regulatory compliance, and downstream application requirements.
Continuous or batch processing may be used based on consumption scale. Key control points include temperature ramp rate, reactant addition rate, pH adjustment, and isolation timing. Impurity ingress frequently links to side reactions and incomplete conversions. Recrystallization or chromatographic purification aims to minimize carryover, with purity verification prior to batch release.
All finished lots undergo layered inspection—including both in-process monitoring and final verification. The final release standard is subject to internal quality control criteria and customer requirements. OOS (out-of-spec) trends trigger root cause analysis and supplier review.
This compound acts as a key synthon for further derivatization. Electrophilic and nucleophilic substitutions are possible at reactive centers, providing access to various dyes, drugs, and intermediates.
Catalyst and solvent selection depend on downstream requirements. High-purity transformations favor inert solvents and minimized by-product formation. Reaction temperature optimization aims to maximize yield while minimizing thermal decomposition.
Major uses include the synthesis of analytical reagents and specialty dyes. Pharmaceutical applications may employ this scaffold for further functionalization, with batch documentation required for traceability in regulated environments.
Effective storage protocols include temperature control—avoiding heat spikes—and protection from humidity and direct light. Dehumidified conditions reduce the risk of hydrolysis and caking in fine powders. Inert gas blanketing may apply at higher purities or for long shelf-life requirements.
Product is packed in compatible polymer or glass-lined containers, as bagging or drum choice depends on batch sizes and distribution chain requirements. Certain packing materials may leach or adsorb product at elevated humidity or temperature, requiring rigorous compatibility evaluation for high-purity applications.
Degradation commonly manifests as color darkening, odor development, and formation of insoluble residues. Shelf life expectations remain lot-specific and contract-driven, supported by ongoing stability testing. Retain samples provide a reference for customer inquiries over the defined holding period.
Classification follows current GHS criteria, with hazard statement and pictogram assignments based on bridging principles and peer-reviewed toxicology. Labeling meets the most stringent jurisdictional requirements among user bases.
Safety data sheets reflect evidence from acute toxicity studies, irritation assessments, and handling incident reports. Precaution statements focus on avoiding inhalation of dust, preventing skin contact, and excluding ignition sources when residual solvent remains above threshold.
Toxicity profiles draw on both animal data and regulatory assessments from the chemical’s primary application industries. Workplace exposure guidelines align with established occupational hygiene standards. Operations use engineered controls such as local exhaust and sealed transfer to minimize exposure for production staff and packagers. Emergency protocols lay out spill response, first aid, and decontamination procedures, continuously updated as regulatory guidance evolves.
As a direct manufacturer, our effective annual output for 1-Phenyl-3-methyl-5-pyrazolone ties closely to raw material cycles and production batch scheduling. Our line flexibility accommodates both pharmaceutical and analytical grades, but available volume can shift depending on upstream phenylhydrazine and acetylacetone stocking. Higher-frequency multi-shift runs support large customer programs, while smaller bespoke batches address speciality requirements. Production planning takes upstream yield drift, reactor turnaround, and purification demand into account, which may affect overall plant throughput during peak demand cycles or prior to regulatory audits.
Minimum order quantity aligns with batch reactor charge sizes set for the customer’s required grade. Larger or customized orders may extend lead time due to process verification, purification slot constraints, and analytic lot-release timing. Typical industrial supply falls within 2–6 weeks depending on grade and packaging choices, driven by batch slot reservation and mandatory QA checks, with expedited cycles reserved for contract customers or critical supply scenarios.
Packaging is grade- and market-dependent. Export lots typically rely on sealed fiber drums or HDPE containers, with liner-material and closure validation based on the product’s moisture sensitivity and purity tier. Specialty pharma or analytical batches may require nitrogen-flushed, double-bagged units, while industrial lots carry tamper-evident closures and serialized batch tags. Packaging integrity is proven by transport stability tests in both ambient and controlled environments, particularly for extended global shipments.
Shipping options include CIF, FOB, and DAP, tailored to end-user compliance requirements and transit risk tolerance. Standard payment terms are net-based by invoice cycle, but variations accommodate long-standing customers with proven credit history. Dangerous goods handling and documentation varies by destination market, and ADR/IMDG compliance for bulk shipments remains a fixed prerequisite. Insurance and detailed chain-of-custody records are maintained especially for regulated market consignments.
Cost basis stems primarily from phenylhydrazine and diketone feedstock volatility. Raw material prices track oil derivative swings and upstream benzene value, frequently distorted by local environmental quotas or plant stoppages at major Chinese, Indian, or European producers. Solvent grade, purification consumables, and waste treatment fees can also tilt the total cost per lot, particularly for high-purity or REACH-compliant output. Any policy shift on hazardous precursors in major economies directly alters forecasted offer validity and inventory risk premiums.
Pharmaceutical and analytical grades reflect higher labor and analytic confirmation cost, while technical and industrial farm grades accept broader specification windows and lower per-kg expenditures. Certified batches with GMP, CEP, or DMF support frequently require supplementary documentation and third-party audit responses, which increases operational and administrative cost allocation. Volumes packed under inert atmosphere or specialty micro-contamination controls fetch higher market prices and require slower batch-approval cycles due to enhanced release analytics.
Global capacity remains dominated by a handful of integrated players in East Asia, with shifting output patterns influenced by Chinese environmental restrictions and Indian process optimization efforts. Supply surpluses usually last until downstream agrochemical or pharma expansion cycles resume, often driven by regulatory approval shifts or seasonal R&D pipeline changes. Customer portfolios in North America, the EU, and Japan emphasize regulatory consistency and backward integration, so demand in these markets tends toward steady, contract-driven purchases versus spot-market spikes.
United States and EU buyers focus on compliance, batch traceability, and consistency, especially for advanced formulation and pharmaceutical uses. Japan’s market emphasizes certification and trace-metals screening typical of electronics and photonic applications, often narrowing suitable supply chains. India drives regional price competition with local synthesis initiatives but wrestles with variable feedstock access and logistical bottlenecks. China’s position—both as supplier and consumer—remains central, affected by periodic anti-pollution restrictions, “green factory” mandates, and occasional plant upgrades or shutdowns for licensing revisions.
Forecasting forward to 2026 involves monitoring regional feedstock trends, regulatory action on key intermediates, and downstream innovation cycles in pharma and specialty chemicals. Tightened environmental compliance in China expects to drive production cost inflation. Indian synthesis expansion improves price competition, but logistics and feedstock bottlenecks remain disruptive. European and US regulatory updates could spur selective demand increases for certified or specialty-packaged material, shifting average price points upward for compliance-supported grades. Methodologically, we aggregate trade data, public regulatory notices, plant operation news, and customer inquiry patterns, discarding anecdotal or non-industrial sourcing.
Recent cycles have seen stricter enforcement of phenylhydrazine handling and environmental emissions at East Asian plants, creating temporary tightening and round-to-round price variability. Several large Indian producers announced plans for backward integration and new EHS-compliant lines late in the review period. Some global supply routes realigned during pandemic logistics disruptions, with certain key accounts shifting to dual-supplier models to mitigate risk.
Environmental and workplace exposure controls for aromatic hydrazines and ketones remain in force across the EU, with ongoing adjustments to REACH registration requirements and updated handling guidance. US EPA review processes have extended compliance lead times for some specialty batches. In Asia, regulatory permissions for plant expansions and new effluent management policies continue to impact site-level operating costs and permitted throughput.
Process departments responded with greater feedstock pre-certification, automation of trace contamination elimination steps, and periodic line upgrades. QA teams stepped up real-time analytics for impurity tracking and batch consistency. Commercial response includes flexible slot allocation, enhanced documentation services for complex certifications, and accelerated logistics for time-sensitive customer projects.
1-Phenyl-3-methyl-5-pyrazolone carries significance as an intermediate and reagent in sectors including pharmaceuticals, fine chemicals, and analytical chemistry. In dye synthesis workflows, it acts as a coupling component or as a masking agent. Pharmaceutical manufacturers use it as a precursor in antipyretic and analgesic formulations; the focus here falls on process impurities, functionality in target product synthesis, and compatibility with downstream process solvents. Analytical laboratories rely on it for complexometric titrations and spectrophotometric measurements, where background purity and low UV-absorbing impurities are critical.
| Industrial Segment | Typical Grade | Critical Parameters | Supplier Quality Focus |
|---|---|---|---|
| Pharmaceutical API Intermediate | Pharma Grade / Custom Purity | High chemical purity, impurity profile, trace solvent residuals | Batch traceability, retention time/release control, cross-contamination control |
| Dye and Pigment Manufacture | Technical Grade | Chromophore response, color body content, water content | Reproducibility, pigment compatibility, absence of background color interference |
| Analytical Chemistry | Analytical Reagent Grade | Low background, absorbance cutoff, absence of UV-visible active impurities | Retention of spectral properties, storage monitoring, limited micro-contamination |
| Fine Chemicals Synthesis | Custom/Technical | Solubility, reactivity, functional stability | Process compatibility, scale-up batch uniformity |
Each application responds differently to grade properties. Fee-for-service API manufacturers push for restricted elemental impurities and a narrow batch-to-batch specification. Dye producers typically request a consistently controlled chromophore content and minimal water, because moisture promotes product clumping and alters shade. Analytical users often return performance feedback tied to spectral baseline clarity rather than only chemical purity.
Start by specifying the end-use context thoroughly—final product, role in synthesis, and regulatory market. For example, a company making finished pharmaceuticals must state if the compound enters synthesis or direct formulation. Dye plants indicate if the molecule will see further chemical treatment or direct pigment creation.
Regulatory environments drive grade selection. Pharmaceutical and certain export pigment lines often require supplier compliance with local pharmacopeias or industry GMP standards. Defining country-specific or market-specific norms at this stage ensures proper quality alignment.
Purity control hinges on both application and downstream risk. Buyers working in regulated drugs evaluate organic volatile impurities, metals, and solvent residues by their impact on finished dose health risk. Bulk dye and pigment makers usually prioritize pigment-forming efficiency and color purity, but not lowest possible trace.
Production scale, campaign batch size, and budget most visibly steer technical versus specialty grade decisions. High-purity lots substantially raise cost as purification volume grows. Accepting a lower grade may be feasible for non-pharma or non-critical syntheses if validated in downstream use and impurity carryover risk is low.
Before finalizing supply agreements, serious buyers perform validation using trial lots—a prudent practical step. Samples allow side-by-side assessment of reactivity, color strength, and purity profile in-line with the intended application. This check unearths incompatibilities or deviations before full-scale adoption.
Choosing precursor quality directly impacts the impurity distribution in the finished product. Suppliers screen incoming batches for key byproduct markers—chlorinated aromatics or excess aldehydes, for example—known to transfer through to the pyrazolone ring.
Process route selection—either batch, semi-continuous, or continuous—responds to both customer segment and impurity trajectory. Dye market requests may tolerate broader impurity spec if color performance meets application checks; pharmaceutical buyers demand tight process design with recurring analytical checkpoints.
Common byproducts arise from over-condensation and solvent breakdown during synthesis. Water content, trace organic acids, and unreacted starting material must be controlled. Purification focuses on recrystallization or solvent extraction stages, yielding grade-limited lots for final screening.
Each manufacturing cycle establishes in-process checks, with in-line chromatography and moisture analysis to decide endpoint timing. This practice holds batch-to-batch chemistry in a narrower range than would be possible by endpoint QC only.
Release typically follows a predefined profile tied to application grade: high-purity grades pass custom impurity screens and tighter acceptance bands; technical-grade lines follow legacy metrics largely dictated by downstream customer feedback and historical process yields.
In industrial-scale synthesis of 1-Phenyl-3-methyl-5-pyrazolone, core operations in our facilities operate under formal quality management systems. Audited certifications such as ISO 9001 reflect the current state of our documented workflows, preventive maintenance, equipment calibration, traceability, and staff training records. Periodic external audits confirm alignment with evolving customer and regulatory frameworks. Consistency of batch processing and documentation practices serves as the foundation for audit compliance, with change controls in place to address process modifications affecting final product integrity.
Certification deliverables depend on the end-use and sector requirements. For pharmaceutical and food applications, third-party audits and certificates such as GMP certification, as well as statements on compliance with region-specific pharmacopeias, appear only where process segregation and trace element controls meet defined thresholds. For industrial and technical grade batches, purity, trace level reporting, and controlled impurity profiles follow negotiated quality agreements and are tied closely to the origin and route of the starting materials. Certificates of Analysis reflect the test batch, grade, and analytical protocol validated for each shipment.
For each production lot, full batch records, including raw material origin, batch process logs, analytical data, and any deviation investigations, are retained to meet traceability and audit request needs. Custom documentation, such as residual solvent test reports, heavy metal screening, REACH pre-registration status, or China RoHS statements, may be provided against specified order or customer request. All documentation is determined by batch status, target market regulation, and project-specific needs. Release documentation tracks amendments arising from in-process analytics or specification changes.
Current annual output is based on dedicated process lines and scalable reactor volume allocations. Raw material procurement ties directly into forward planning, allowing buyers to reserve guaranteed slots for large-scale requirements or opt for staged delivery contracts. For markets with fluctuating demand, we enable buffer stock agreements and expedited campaign runs. Buyers selecting technical, standard, or high-purity grades receive capacity reservation terms reflecting their risk tolerance and lead time needs.
Capacity assurance is built on redundancy in process equipment, supplier qualification for critical reagents, and real-time production management systems. Any supply interruption triggers alternate sourcing protocols and prompt status reporting. Long-term commercial partners give input to our production master plan, allowing synchronized scale-up and dynamic reprioritization in line with market changes.
Sample provision initiates with the technical requirement review by our application chemists, clarifying grade, analytic method, and purpose. Pre-shipment sample lots are drawn from representative routine production, not lab-scale synthesis, ensuring actual batch performance reflects supply chain reality. Analytical method sheets, material safety documentation, and sample handling guidance accompany every trial shipment.
To stabilize supply risk, we structure blanket orders, rolling forecasts, and volume-based rebate programs. Contract manufacturing terms and toll synthesis routes are available where buyer-supplied intermediates or joint impurity control protocols are needed. For new project launches, technical teams conduct joint process reviews and manage validation batch runs, with transparent reporting of yield, impurity drift, and scale-dependent factors. Buyers seeking exclusivity or process customization can engage in multi-phase negotiation covering IP handling, raw material supply chain mapping, and on-demand documentation sharing.
Technical departments working with 1-Phenyl-3-methyl-5-pyrazolone focus research efforts on three main directions. Analysts and synthesis chemists pay close attention to optimizing selectivity and purity for its established roles as an intermediate in pharmaceutical and dye manufacturing. Quality control teams monitor how purification steps affect the removal of colored and non-volatile impurities typically encountered in large-scale lots. Meanwhile, application labs investigate formulation compatibility with solvents and binders common in downstream production, scrutinizing interactions that might introduce haze or discoloration.
Process development engineers observe increasing inquiries from developers of electronic materials and specialty ink sectors. In display and print technology, the product’s coordination ability draws attention for roles outside classical chelation—such as pigment modification and as a precursor for specialty colorants. The move from legacy chemistry to tailored functional molecules brings new requirements for low trace metals and customer-driven purity profiles, prompting further investment in flexible purification units.
Sustained pilot and plant-scale R&D aims to contain byproduct formation during synthesis. Unwanted condensation side-products, common in certain batch routes, require selective crystallization and solvent-switch techniques. Projects run by our plant engineers have yielded tighter control schemes, reducing batch-to-batch variability in the final assay. Recently, improvements in raw material pre-treatment and loop purification options have lowered colored impurities—a change reflected in sharper product clarity, especially in optical and analytical grades. Monitoring for trace chlorinated and nitrogenous byproducts in real time enables proactive process adjustments, supporting regulatory compliance and minimizing downstream risk.
Demand trends depend heavily on downstream pharmaceutical and high-value dye market performance, which is sensitive to regulatory shifts and innovation in end-use technologies. Expectations suggest incremental growth, with regions focused on inkjet and display technology showing the fastest adoption rate of advanced purity grades. Producers with integrated purification and waste management capacities position themselves to benefit most as customer specifications tighten.
A shift away from batch to continuous process approaches shapes development priorities. Advanced real-time monitoring technologies, such as in-line spectroscopy and feedback-controlled dosing, help maintain tighter product consistency. Integrated impurity trapping—where unwanted byproducts are sequestered during the reaction stage, before purification—enhances batch releases with reduced rework incidence. These improvements respond directly to queries from formulators facing stricter reliability and trace impurity limits in specialized coatings and pharmaceutical intermediates.
Pressure from downstream markets leads to active work in greener synthesis. Process chemists trial alternate, less hazardous solvents and recycling of process water on pilot installations. In the QC lab, teams track total solvent load per ton output, preferring processes that yield higher product per input with lower carbon and waste ratios. Regulatory compliance in key export markets, especially Europe and North America, already requires producers to report residual levels of certain impurities and prioritize source material traceability.
As a manufacturer, we deliver technical consultation based on real production scenarios. Customers receive direct guidance on raw material compatibility, formulation troubleshooting, and impurity impact. Our technical team evaluates customer sample needs, offering joint interpretation of analytical data when non-conformance or anomalies occur. Application support considers the grade’s intended use and shade outcome, providing technical explanations rooted in current QMS practices and batch history reviews.
Process engineers and lab specialists provide hands-on advice for process adaptation, including switching between grades, solvent systems, and blending protocols. Clients working on novel ink or pharmaceutical intermediates can request dedicated support for scaling and formulation, including pilot sample runs and technical workshops. Where issues trace to grade sensitivity—such as color drift or instability on standing—our team reviews root cause, potentially offering tailored pre-treatment or reprocessing recommendations.
Post-shipment, the technical and QA units remain available for site-specific support, whether for confirming product identity, managing batch differences, or assisting with compliance documentation needs. Investigation procedures include retained sample reanalysis, lot reconciliation, and, where necessary, technical site visits. Our after-sales protocols anchor resolution in transparent communication and traceability, underpinned by internal release and retention policies that comply with relevant regulatory obligations for each sold grade.
Operating as a specialty chemical manufacturer, we produce 1-Phenyl-3-methyl-5-pyrazolone through in-house synthesis and downstream purification processes. Rigorous monitoring throughout the entire production chain limits by-product formation and ensures consistency between batches. Raw materials arrive only after strict in-house analysis, and every critical reaction stage runs under closed-system conditions. Our operators maintain full traceability, supported by automated batch tracking, which keeps records not only of starting materials but of every process step until packaging.
Consumers in the pigment, pharmaceutical intermediate, and chelating agent markets rely on this compound for its performance characteristics. In the pigment sector, reagent-quality 1-Phenyl-3-methyl-5-pyrazolone remains the preferred intermediate for azo dye synthesis, providing chromatic stability batch after batch. Downstream pharmaceutical processors select it for compatibility when producing analgesics and anti-inflammatory agents. In metal analysis labs, its chelating functionality provides a reliable basis for spectrophotometric determination of trace metals. The product’s purity grade supports sensitive analytical routines and reaction sequences without introducing interfering substances.
Manufacturing oversight ensures every shipment meets defined physical and chemical parameters. Each lot receives a complete composition profile using NMR, HPLC, or GC analysis based on end-use needs. We reject lots that fall outside narrow impurity thresholds. Our laboratory evaluates stability under typical conditions, providing both immediate compliance data and long-term retention reports. End users can expect repeatable performance, whether processing hundreds of kilograms or optimizing small-scale pilot batches.
Packaging operations integrate directly with production scheduling, allowing supply flexibility from drum to bulk container or palletized units, sealed for moisture and contamination control. Labeling follows clear serialization standards, meeting both domestic and international logistics requirements. Each unit stays traceable to the production date and quality documentation, minimizing delays and misrouting. We maintain buffer inventory at strategic points to support rapid shipment for scheduled orders and urgent requirements. Our logistics team handles compliance with transportation standards, supporting direct delivery to industrial facilities, contract processors, and global warehousing partners.
Technical staff work directly with buyers’ R&D and process teams to address application-specific requirements, whether scaling to new dosage forms or adjusting blending conditions. Internal expertise covers both molecular synthesis and downstream processing challenges, allowing feedback that often leads to production adjustments in real time. Each inquiry receives support from trained staff with practical operating knowledge, not detached sales or brokerage teams. Analytical data for each batch can be provided upon request to satisfy inspection or validation procedures in regulated sectors.
Direct procurement from the manufacturer ensures access to process documentation and thorough product stewardship. Buyers gain from scheduled deliveries aligned with downstream workflow and project planning. Distributors and supply chain managers can depend on established supply practices and technical transparency that minimizes uncertainty or hidden costs. In competitive and time-sensitive sectors, direct connection with the factory eliminates ambiguity, supporting procurement objectives, regulatory compliance, and quality targets under high-volume or specialty project conditions.
As a manufacturer with large-scale experience in producing 1-Phenyl-3-methyl-5-pyrazolone, our operations rely on a clear understanding of its chemical behavior, especially its solubility in various organic solvents. This isn’t just a technical detail; solubility impacts our purification, crystallization, and downstream handling, directly influencing process efficiency and final product quality.
Preparing every batch for pharmaceutical, pigment, or analytical applications starts on the factory floor by addressing how 1-Phenyl-3-methyl-5-pyrazolone interacts with solvents. Our regular process audits have shown this compound dissolves efficiently in polar aprotic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) at ambient temperature. We see rapid dissolution during process trials and minimal residue left after standard mixing. This permits us to use these solvents for precise crystallization and purification steps.
Solubility in ethanol and methanol lands at moderate levels in our tests. Grinding, mixing, and heating are generally required for full dissolution. In IPA, we notice rates much lower compared to methanol, so plant operations sometimes require longer agitation periods. Limited solubility in acetone or ethyl acetate requires us to pre-dissolve the material when clean recovery is critical. For customers formulating with ethyl acetate or acetone, intermediary dissolution in DMSO followed by anti-solvent precipitation delivers usable results.
Direct observations during production demonstrate negligible solubility in water. Even after extended stirring or heating, crystals remain undissolved, confirming the practical need to avoid aqueous routes for purification. Our experience extends to common hydrocarbons such as hexane, toluene, or heptane. Here, dissolution rarely exceeds trace levels, so these solvents mainly serve utility roles such as washing rather than for main process solubilization.
Managing solvent handling has daily consequences for both safety and waste minimization. DMSO and DMF provide broad solvating power, but plant protocols stress proper containment due to environmental and worker-exposure risks. Lower-solubility solvents, like acetone, simplify waste treatment but demand more mechanical effort—mixing, filtration, and temperature control. Where possible, we tailor solvent use to batch size and downstream requirements, always balancing yield, purity, and compliance. Our technical team runs pilot batches to optimize solvent consumption and develop protocols to reduce solvent waste.
Our customers often ask us which solvents line up with their project requirements. Whether formulating analytical reagents or manufacturing intermediates, direct access to solvent-solubility insight saves valuable time during scale-up. Our support team draws directly from factory-scale learning—translating those observations into efficient protocols. For companies working with new organic matrices, we can share best-practice operational notes and recommendations on processing temperatures and solvent combinations drawn from our own experience.
Our production experience with 1-Phenyl-3-methyl-5-pyrazolone comes from years of practical application, batch production, and technical troubleshooting. Customers benefit from direct manufacturer knowledge, streamlining formulation and scale-up with the right solvent choices, increasing yield, and maintaining process safety and product purity. For proprietary project needs or further technical specifications on solvent compatibility, we provide up-to-date, factory-tested data and support.
Current global buying sentiment for 1-Phenyl-3-methyl-5-pyrazolone looks active, yet logistics and raw material demand continue to present real challenges. Buyers often ask about stock realities and delivery timelines, so it’s worth clarifying where things stand from the factory floor and what influences the path from order placement to delivery dock.
We maintain regular production schedules according to contract planning, average order forecast, and actual sales peaks. Short-notice fluctuations in upstream chemical supplies sometimes affect batch start dates. Drawing insight from this year’s actual shipment cycles, average lead time for large-lot orders currently spans three to five weeks from confirmation, with shipping schedules slightly longer when supply chains tighten or custom packaging is required.
Moving bulk freight across international lines calls for prompt coordination between our plant logistics, freight handlers, and final receivers. Our warehousing tries to keep a buffer on-hand to support priority customers. Large volume planning keeps costs and delays in check, so we encourage customers to communicate expected annual or quarterly needs, especially for larger drums or unusual pallet configurations. Good forecasting not only cuts wait times but helps anticipate force majeure events before they become global headlines.
Our production and filling lines handle several practical packaging configurations to support large consumers and contract manufacturers. Standard commercial offering for 1-Phenyl-3-methyl-5-pyrazolone covers:
Bulk tank loading remains available for larger chemical parks or integrators with infrastructural capacity. Our filling team monitors product transfer and sealing integrity on every unit; this isn’t left to chance. The choice of packaging often relates to the downstream process – each form keeps product dry, protected from UV, and fully traceable.
Sometimes, end users in regulated markets have special transfer methods, so we can supply fit-for-purpose documentation and help address common compliance headaches. Supporting documentation, like certificates of analysis and stability data, is sent directly from our lab with every production lot dispatched.
From a manufacturer’s seat, most scheduling issues land on our desk based not on production alone, but on coordinated material flow and real signals from buyers. Empty promises help no one, so every quote and delivery window gets stress-tested against plant operating realities. Bulk purchases draw on real capacity— not just brokerage. Building trust means staying transparent about lead times, honest about achievable lot sizes, and ready to discuss operational restrictions openly.
Our existing customers value fast, reliable feedback on packaging variants and lead time projections. Both bottleneck and out-of-policy requests are reviewed in real time by actual production managers— not automated systems— so we respond to real-world questions, as they come. Our upstream procurement team negotiates directly with material producers, keeping a close watch on safety and environmental requirements, especially for bulk batches leaving port.
Our long experience producing 1-Phenyl-3-methyl-5-pyrazolone means we respect the need for visible, predictable supply. That means talking openly about what’s possible, and always backing up allocations with what we have in the plant or on the dock— never overpromising on what the market can’t realistically deliver. For details on technical documentation, specialized packing, or tailored lead time forecasts, our team stands ready to answer with direct, factory-based knowledge.
Manufacturing 1-Phenyl-3-methyl-5-pyrazolone means handling export compliance and safe logistics right from our own plant. Our team does not just know the chemistry; we track each regulation touching the movement of this compound across borders.
1-Phenyl-3-methyl-5-pyrazolone, also recognized in international markets as PMP, does not appear on major hazard lists such as the IATA Dangerous Goods Regulations (DGR) or the IMDG Code for marine transport. It does not carry a UN number, and, based on standard classification, quantities we provide do not meet criteria for “dangerous goods” status under GHS or CLP labeling. Still, regulations shift fast. We maintain in-house regulatory staff to keep each shipment’s paperwork reflective of the latest requirements imposed by customs and enforcement agencies.
Import countries may apply their own chemical control policies, even for materials not treated as hazardous in the point of origin. Our logistics group completes Material Safety Data Sheets (MSDS) in both English and, where needed, in destination languages—ensuring customs and port authorities see the same technical profile we do. For customers in the EU or Asia-Pacific, we generate REACH or K-REACH compliance documentation on actual batch data, not sample figures. Such documents bear traceable factory lot numbers, linking each drum or bag directly to our production logs.
We fill containers on-site and apply labels with all required pictograms, chemical identifiers, and precaution statements as demanded by the market of use. If a customer’s country asks for a particular secondary label—such as waste handling or shelf life—we apply that during production, not at the dock or warehouse. Our shipping team audits all packaging before it leaves our gate, capturing photos and weights for later tracking.
Because border controls vary widely, we furnish any further technical data that importing authorities demand, such as certificates of analysis, batch manufacturing records, or origin details. Every document references our company as actual originator and manufacturer, not a secondary consolidator. We regularly update our export declarations to reflect changing dual-use or precursor rules, removing any ambiguity that might slow international release. This hands-on approach saves our clients from facing compliance holdups or having cargo flagged in transit.
Among the main compliance challenges: differences in customs codes or local environmental licensing in the destination country. We run checks on HS codes and trace chemicals against restricted lists each time we prepare a transport. If client-side regulators request product-specific toxicity or biodegradability data, our technical department issues the relevant studies based on in-house analysis, not reprints or external summaries. This active verification gives clients direct access to manufacturing details supporting their own internal regulatory audits.
Every international shipment of 1-Phenyl-3-methyl-5-pyrazolone from our factory includes live regulatory tracking, sale-backed certification, and transparent packing. We act as primary holder of all compliance information, not just a conduit between third parties and official authorities. Operating as the manufacturer, our responsibility covers the entire chain from loading bay to customs clearance, enabling our clients to import and use this compound without losing time to paperwork or compliance questions.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales7@bouling-chem.com, +8615371019725 or WhatsApp: +8615371019725
